H ypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by left ventricular (LV) hypertrophy without dilatation and without apparent cause (ie, it occurs in the absence of severe hypertension, aortic stenosis, or other cardiac or systemic diseases that might cause LV hypertrophy). Numerous excellent reviews and consensus documents provide a wealth of additional background. [1] [2] [3] [4] [5] [6] [7] [8] HCM is the leading cause of sudden death in young people and leads to significant disability in survivors. It is caused by mutations in genes that encode components of the sarcomere. Cardiomyocyte and cardiac hypertrophy, myocyte disarray, interstitial and replacement fibrosis, and dysplastic intramyocardial arterioles characterize the pathology of HCM. Clinical manifestations include impaired diastolic function, heart failure, tachyarrhythmia (both atrial and ventricular), and sudden death. At present, there is a lack of understanding of how the mutations in genes encoding sarcomere proteins lead to the phenotypes described above. Current therapeutic approaches have focused on the prevention of sudden death, with implantable cardioverter defibrillator placement in high-risk patients. But medical therapies have largely focused on alleviating symptoms of the disease, not on altering its natural history. The present Working Group of the National Heart, Lung, and Blood Institute brought together clinical, translational, and basic scientists with the overarching goal of identifying novel strategies to prevent the phenotypic expression of disease. Herein, we identify research initiatives that we hope will lead to novel therapeutic approaches for patients with HCM.
Epidemiology
The epidemiology of HCM suggests that it is present in Ϸ1 in 500 adults. 9 Because of the delay in phenotypic expression of the disease, HCM is not commonly recognized clinically in young children, but when it is, it is much more frequently recognized in males. 10 This is likely due to greater penetrance in young males. 11, 12 HCM is underdiagnosed clinically in blacks and in women, yet women tend to present with more marked heart failure than men when they are diagnosed later in life. 13, 14 There is no overall difference in mortality, including sudden cardiac death, between men and women, although sudden cardiac death on the athletic field predominantly occurs in men.
Genetic Cause
Extensive investigation has shown that at least 50% of HCM cases can be traced to a specific genetic cause. This probably underestimates the true percentage of genetically based HCM, because current mutation-screening platforms typically examine only 8 to 10 genes because of unfavorable cost-benefit assessments. For example, current platforms do not examine titin (owing to its size) or myozenin-2 (because relatively few mutations have been defined in this gene). 15 Moreover, when strict clinical criteria are used for diagnosis, including family history, mutation detection approaches 70%.
HCM is a genetic disease of sarcomere proteins, 5, 16 with mutations in the genes that encode ␤-myosin heavy chain (MYH7) and myosin binding protein C (MYBPC3) accounting for Ϸ80% to 85% of cases with identified mutations in most series. 4, [17] [18] [19] Mutations in the troponins cardiac troponin T (TNNT2) and troponin I (TNNI3) and ␣-tropomyosin (TPM1) are also relatively common, collectively representing 10% to 15% of additional genetic causes for all HCM cases. 4, 17, 19 These and the myosin light chains (MYL2, MYL3) and ␣-cardiac actin (ACTC) are the 8 genes most commonly involved in HCM.
Rare Genetic Causes
Mutations in several other genes that encode sarcomere or sarcomere-related proteins have been implicated in HCM, including cardiac troponin C (TNNC1), ␣-myosin heavy chain (MYH6), and cardiac myosin light chain kinase 2 (MYLK2). In addition, several other genes that encode nonsarcomere proteins, including caveolin 3 (CAV3), calreticulin (CALR3), junctophilin-2 (JPH2), phospholamban (PLN), and the mitochondrial tRNA-encoding genes MTTG and MTTI, produce clinical features that mimic HCM. 4, 20 The relationship of HCM caused by sarcomere protein gene mutations to these disorders is unclear. 5, 16 
Unknown Causes
The apparent absence of mutations in patients with a clinical diagnosis of HCM indicates an important gap in our knowledge. Mutation testing can be particularly uninformative in 3 clinical scenarios in which family history is negative: (1) Hypertrophy that occurs very early in childhood; (2) hypertrophy that is only recognized after middle age; and (3) hypertrophy that is limited to the ventricular apex. 21 The cause of these conditions is not clear.
Disease Mechanisms
The disease mechanisms of HCM remain incompletely understood. Postulated mechanisms include (1) a dominant negative function (ie, a "poison peptide," wherein the mutant gene encodes a protein that interferes with the function of the normal allele); (2) haploinsufficiency (leading to an insufficient quantity of the normally functioning sarcomere protein); and/or (3) impaired myocardial energetics and decreased energy reserve. 8, 22, 23 The lack of a definitive link between mutations and an understanding of the pathogenesis/molecular mechanisms that drive the expression of the HCM phenotype is a significant gap in our understanding of the disease.
Clinical Genetics
Allelic heterogeneity (each family having a so-called private mutation) is particularly common in HCM. Approximately 500 mutations have been noted in the medical literature, but the number of identified mutations in various private databases suggests the true number is more than 1000. HCM demonstrates age-dependent penetrance, affecting 50% to 80% and 95% of individuals by age 30 years and ages 50 to 60 years, respectively. 24 Recent estimates of 1% annual mortality in HCM differ significantly from earlier estimates (3% to 6%) that were based on referral populations of high-risk groups to HCM centers. [25] [26] [27] Survival to 75 years or beyond has been estimated in Ϸ25% of an unselected HCM cohort. 28 
Compound Heterozygosity
Two to five percent of patients with HCM harbor 2 mutations (compound or double heterozygosity) or are homozygous for a mutation, 4, 18, 29, 30 and these patients display more severe and/or earlier onset of disease. 29, 30 Genotype/Phenotype Relationships Despite the significant clinical heterogeneity observed even for the same mutation within families or between families, [31] [32] [33] [34] [35] as well as the variable penetrance, which alters clinical onset and severity of disease, genotype/phenotype relationships of sarcomere gene mutations clearly have advanced our understanding of the disease and, in some cases, have allowed identification of relatively low-versus high-risk patients. 36, 37 Some genotype/phenotype relationships that have stood the test of time include MYH7 mutations, which are associated with earlier onset and more extensive hypertrophy. 8, 33, 35 More specifically, the myosin 403 mutation is associated with increased risk of heart failure and sudden death, and the myosin 719 mutation leads to a marked increase in heart failure. Others include the relatively limited hypertrophic response with TNNT2 mutations 34, 38, 39 and the incomplete penetrance and relatively later onset of HCM from MYBPC3 mutations. 31, 36, 40 That said, multiple poorly understood mechanisms contribute to heterogeneity of presentation, and these include environmental inputs, sex, 10 and genetic and epigenetic modifiers.
Key Morphological and Clinical Components of Genetically Mediated HCM
Cardiomyocyte and cardiac hypertrophy, myocyte disarray, interstitial and replacement fibrosis, and dysplastic intramyocardial arterioles characterize the pathology of HCM. Clinical manifestations include impaired diastolic function, tachyarrhythmia (both atrial and ventricular), and sudden death. [41] [42] [43] [44] Accepted risk factors for sudden cardiac death include prior cardiac arrest from ventricular fibrillation, spontaneous sustained ventricular tachycardia, family history of premature sudden death, unexplained syncope, LV wall thickness Ն30 mm, abnormal blood pressure response to exercise, and nonsustained ventricular tachycardia. 28, 43 Additional predictors include the presence of LV apical aneurysms and the end stage of disease. 45, 46 A consensus document 1 and review 47 of clinical management of arrhythmias and sudden cardiac death in HCM are available. Clinically apparent atrial fibrillation develops in at least 20% of patients with HCM, 48 but the true incidence is likely higher than that. Atrial fibrillation is a risk factor for thromboembolic disease, including stroke. 1 Molecular mechanisms that regulate the phenotypic expression of the various pathologies and how these might drive arrhythmogenesis in HCM are poorly understood.
Genetic Causes of LV Hypertrophy Not
Involving Sarcomere Mutations 
Rationale for Investing in Research on HCM
The rationale for investing in research in HCM is supported by the following: (1) HCM is the most common genetic heart disease and affects individuals at every age; (2) HCM is the most common cause of sudden death in young people; (3) HCM is an important cause of heart failure disability; (4) HCM can be viewed as a paradigm for the potential opportunities provided by harnessing modern genetic science in medicine to make gene-based diagnosis and prediction a reality; (5) gaps in our basic understanding of mechanisms of disease are substantial, but already, insights provided by studies in patients and in animal models of HCM suggest creative strategies to alter the natural history of this disease; and (6) these insights also promise a greater understanding of the molecular pathophysiology of other, nongenetic causes of hypertrophy. Thus, we believe that there are unparalleled opportunities in the immediate and near future to translate basic insights about HCM into new clinical models for diagnosis, prevention, and therapy.
Critical Deficits in Our Understanding of HCM Pathogenesis Define Research Initiatives
In the online-only Data Supplement to this report, we define key deficits in our understanding of HCM, thereby leading into a delineation of research initiatives for the future. The areas of research will be broken down into clinical, translational, and basic science sections, but these divisions are clearly arbitrary and only serve as an organizational (and not operational) tool. In fact, we will strive to maintain connections among the 3 divisions, focusing on common deficits in our understanding.
Sources of Funding
The following receive research grants from the National Institutes of Health (NIH), Howard Hughes Medical Institute (HHMI), the Fondation Leducq (FL), The American Heart Association (AHA) Application of contemporary genetic and genomic strategies will help to answer these questions. Comprehensive sequence analyses of myocardial tissues can assess the role of somatic mutation in HCM. Developing cohorts of mutation-negative HCM patients can direct family-based and population-based genome-wide studies to define new genes and risk alleles. 6 Early clinical studies of mutation-positive versus mutationnegative HCM have begun to suggest differences in morphologic manifestations and clinical outcomes. 4 By defining the cause of disease in mutation-negative HCM, there is an opportunity to discover cell and molecular responses triggered by these genetic etiologies, and the potential for gene-specific therapeutics. More broadly, this knowledge base will provide a more comprehensive understanding of molecular triggers for cardiac remodeling, data that may be relevant to a wide range of cardiac pathologies.
B.
The natural history of HCM should be more clearly defined.
Recommendation: Support a prospective study of the natural history of HCM.
Large referral centers have utilized their own referral populations to define the natural history of HCM, including identification of risk factors for progression to heart failure and for sudden cardiac death. [7] [8] [9] [10] [11] [12] These studies provided important insights and constitute much of the basis for current treatment guidelines for patients with HCM and for their family members. 12 That said, much of the data provided by these studies has one or more limitations including relatively small sample sizes, center-specific differences in diagnostic criteria for HCM, and differences in practice patterns and patient follow-up.
Importantly the definition of HCM utilized by many cohort studies are based on clinical criteria and fail to capitalize on genetic information that precisely define patients with the same or different etiology.
In the past, studies of the natural history of HCM could not take advantage of emerging imaging techniques (e.g. MRI), new strategies to assess arrhythmic risks (e.g.
circadian rhythm patterns or long-term arrythmia monitoring with implantable devices) or newer biomarkers [13] [14] [15] [16] [17] [18] [19] [20] [21] . Although some of these approaches are being studied in selective centers, results may reflect referral populations, similar to earlier clinical studies. We believe that new tools are now in place to establish a multi-center prospective observational cohort study of HCM that is predicated on genotype. 22 Application of the same comprehensive sequencing strategies to define pathogenic mutations in HCM patients described above will provide clinical researchers with a rigorous framework for Recognizing that there will be a trade-off between sample size and the number and complexity of assessments performed on each subject, this study should emphasize sample size over complexity so that sufficient power will be available to study genetic subgroups. This research is expected to yield substantial and generalized insights into the diagnosis and progression of HCM that will refine clinical practice. In addition, it will provide a substrate for translational studies of biomarkers and possibly cardiac tissue and aid in design of clinical trials by identifying subgroups of HCM patients that may benefit the most from specific treatment strategies.
C. There is a paucity of evidence-based treatment strategies for HCM patients. Although we fully realize that the state of current knowledge does not allow us to identify a specific intervention to test at this time, this section will outline the rationale for, and potential design of, a theoretical clinical trial, including possible surrogate endpoints and pitfalls, should a candidate intervention be identified in pre-clinical studies (see below) and supported in early phase clinical trials.
Current therapeutic approaches to HCM.
The medical management of HCM has been largely unchanged over the past decades 23 and in contrast to therapies for ischemic heart failure, treatment recommendations in HCM are based on observational series without prospective randomized controls. Contemporary approaches to management are discussed more fully in the following references. 12, 24, 25 While clinical usage provides support that various pharmacologic agents reduce HCM symptoms, no evidence has demonstrated that they alter disease progression or outcomes. With the discovery of causal gene mutations and the development of animal models that allow interrogation of pathogenic mechanisms, research is needed to consider newer strategies in HCM. With the ability to identify individuals with HCM mutations in advance of clinical disease, opportunities should be explored to find therapies that impact the natural history of HCM by preventing, or attenuating the emergence of myocardial phenotypes.
A major goal in treatment of HCM is to limit the life-threatening consequences of arrhythmia. As precise triggers for arrhythmias that produce SCD in HCM are unknown, management strategies aim to treat high risk patients (defined by factors detailed above) with implantable cardiac defibrillators (ICD). While these devices can avert SCD and confer a favorable risk-benefit ratio, 26 more robust parameters that discriminate between HCM patients who will vs. will not benefit from ICD implantation are needed.
Furthermore, while no anti-arrhythmic agents have been shown to prevent SCD, novel agents may emerge, and their efficacy could be assessed in high risk patients with ICDs already in place.
For patients with symptoms related to left ventricular (LV) outflow obstruction, current therapies aim to diminish the mechanical obstruction. 23, 25 When symptoms are refractory to medical therapy, surgical septal myectomy is warranted. [27] [28] [29] [30] The development of catheter-based alcohol septal ablation, can benefit select patients, although long-term experience with this procedure is limited and its appropriate use continues to be debated. [27] [28] [29] [30] Well-controlled trials involving these treatment options would add substantially to clinical management of HCM.
AF may be poorly tolerated in patients with HCM, and rate control or measures to convert to sinus rhythm are important aspects of therapy. 31 In patients with a history of AF, chronic anticoagulation is essential. Knowledge of why AF is substantially increased in HCM and strategies to prevent this arrhythmia would benefit large numbers of HCM patients.
Potential drug therapies and novel targets for intervention
At present, none of the routinely employed pharmacologic therapies for symptomatic patients with HCM have been demonstrated to impact beneficially on the natural history of HCM. 12 Furthermore, it is unclear whether any currently available drug therapy can prevent (or limit) the development of phenotypic manifestations of HCM in individuals identified as carrying a known disease-causing sarcomere mutation. That said, some preclinical evidence supports the potential benefit of drugs that block the renin-angiotensinaldosterone system (RAAS). 21, 32, 33 In patients with HCM, serum levels of aldosterone are increased up to 4-fold compared to normal controls, a finding which is accompanied by increased levels of serum markers of collagen turnover and abnormalities of diastolic function. 17, 21 In addition, several recent studies using transgenic mouse models of HCM have demonstrated up-regulation of the RAAS. 21, 33 Spironolactone has been shown to reduce both coronary microvascular remodeling and fibrosis and to improve diastolic function in mouse models of HCM expressing human sarcomere mutations. 21, 33 However, similar strategies in the feline HCM model have not shown similar benefit. [34] [35] [36] Four small pilot studies in patients with non-obstructive HCM have reported that angiotensin receptor antagonists led to borderline improvement in various parameters. [37] [38] [39] [40] Most recently, Penicka et al. have reported benefits with candesartan (reduced LVH and improved exercise tolerance). They also reported that treatment effects may be dependent on the specific sarcomere mutations, although this, as with all clinical trials to date in HCM, was too small to draw any definitive conclusions. At present, it is not clear whether targeting the RAAS in HCM will be beneficial in patients, but at least the studies suggest the angiotensin receptor antagonists are safe in non-obstructive disease.
Studies in mouse models suggest that other strategies might be effective. For example, the L-type calcium channel inhibitor, diltiazem, has had beneficial effects in two HCM models-the α-myosin heavy chain(403/+) and TnT 179N mutations. [41] [42] [43] Diltiazem is currently being examined in patients with documented HCM mutations but with no evidence of phenotypic expression of disease to determine whether it can prevent clinical manifestations (http://clinicaltrials.gov; trial # NCT00319982). Data from animal models also support a potential role of statins 44, 45 (though a recent pilot study in patients showed no effect on hypertrophy or contractile function 46 ). Emerging evidence suggests that targeting BMP and TGFβ signaling in the heart may hold promise as well, particularly for blocking the fibrotic response (see Basic studies, section D). In fact, RAAS inhibitors likely act, in part, by inhibiting TGFβ. However, much more preclinical work needs to be done with this system. 47, 48 Clearly, there is a critical need for future research considerations directed toward basic and translational studies to identify putative targets for intervention (see below).
When viable targets are identified, clinical studies should be undertaken to determine if novel (or currently available) drug, or other therapies, can target these pathways of HCM disease expression and, thereby, improve on the natural history of patients with this disease.
Challenges for clinical trials in HCM.
There are important obstacles to prospective, randomized clinical trials in patients with HCM, most notably the low overall event rate. For sufficient enrollment, participation by multiple centers would be needed. Furthermore many "hard" or objective outcomes in HCM, occur after many years (e.g. heart failure) or are uncommon (e.g. sudden cardiac death, for which the estimated event rate is ~1% per year). Thus prospective trials to assess the efficacy of new drugs or devices to reduce these HCM outcomes would require enrollment of large patient numbers studied for many years.
Furthermore, genetic and phenotypic diversity in HCM would make individual patient randomization even more challenging. Despite these challenges, prospective trials that use surrogate end-points in HCM may be feasible. 
Potential pathophysiologic targets and surrogate endpoints in HCM.
Among the potential surrogate endpoints in HCM, one focus could be on myocardial dysfunction capitalizing on newer imaging modalities (i.e., MRI, tissue doppler imaging and strain). 49, 50 Alternative endpoints with probably more promise, given apparent linkage to clinical outcomes, include measures of myocardial ischemia, myocardial hypertrophy (LV mass), and fibrosis. The severity of abnormalities in these endpoints may be more closely linked to the adverse clinical course, including a propensity to worse symptoms, arrhythmias and progressive myocardial dysfunction.
In HCM, the mechanism of myocardial ischemia is likely related to structurally abnormal intramural coronary arterioles, resulting in microvascular dysfunction, reduced vasodilator reserve, limiting myocardial blood flow (MBF) during stress. Previous studies that employed contemporary cardiovascular imaging modalities such as single photon emission tomography (SPECT), positron emission tomography (PET) and cardiovascular magnetic resonance imaging (CMR), have demonstrated that HCM patients have impaired MBF following dipyridamole administration. [51] [52] [53] [54] Impaired MBF is a powerful independent predictor of adverse LV remodeling and of cardiovascular mortality. 51, [55] [56] [57] Among these imaging modalities, CMR may be particularly advantageous for patients with HCM by providing, in one examination, detailed characterization of the pattern and distribution of wall thickening, as well as an assessment of myocardial perfusion and fibrosis, with high spatial resolution and without ionizing radiation. 58 With intravenous gadolinium administration, CMR perfusion sequences permit both qualitative and quantitative assessment of MBF at rest and during pharmacologic stress with superior spatial resolution compared to PET or SPECT. 54 Furthermore, after the acquisition of the first-pass perfusion images, late gadolinium enhancement sequences (LGE-CMR) can identify the presence (and quantitatively measure the extent) of myocardial fibrosis in HCM patients. 59, 60 LGE may be one surrogate endpoint since HCM patients with the most marked reduction in ejection fraction have more extensive LGE than patients with preserved systolic function. 59, 60 Holter monitoring shows ventricular arrhythmias are also more common in HCM patients with LGE than HCM patients without LGE. 61, 62 Whether CMR can delineate an unstable arrhythmogenic substrate and identify patients at risk for sudden cardiac death warrants study.
PET and CMR studies in HCM patients demonstrated blunted MBF in response to stress. 54, 63 Moreover HCM myocardium that is near to, or contains regions with LGE are often associated with reduced MBF by PET and CMR. 64, 65 Taken together, these observations suggest that myocardial ischemia may contribute to myocyte death and ultimately replacement fibrosis. 66 These data support efforts to determine if myocardial ischemia precedes LGE-labeled myocardium in HCM, and assessment of whether strategies to mitigate ischemia might prevent myocyte death and the emergence of replacement fibrosis in HCM. Ischemia and fibrosis also represent potential pathophysiologic targets for therapeutic intervention using existing or novel drug therapy.
Based on these findings, imaging markers of myocardial ischemia, along with those for pathologic hypertrophy and fibrosis, represent prime candidates to serve as surrogate endpoints for clinical investigation into the role of various prevention and treatment strategies.
Construct of a potential clinical trial in HCM.
A clinical trial aimed at determining the efficacy of drug therapy in altering but it will be difficult or impossible to power an initial study for clinical outcomes, based on the low event rates in this population. Nevertheless, strong consideration should be given to incorporating specific clinical events, such as death or life-threatening arrhythmia, into a composite endpoint, along with a disease marker such as progression to LVH. However, because LVH and fibrosis are relatively late markers of disease, multiple potential biomarkers of disease progression should also be examined. These should include serum markers of fibrosis and collagen turnover (e.g. the pro-sclerotic cytokines and the protease/anti-protease systems, TGFβ 1 , IGF-1) 67 and markers of myocyte stretch, hypertrophy, and injury (e.g. natriuretic peptides and troponin).
Beyond the primary endpoint, such a trial would be an outstanding opportunity to track the natural history of patients with genotype-positive HCM and to gather pilot information on the effects of drug on other manifestations of disease. Ultimately, the study will help provide further insight into which HCM patients are at highest risk for developing progressive adverse remodeling and arrhythmia.
II. Translational Initiatives.
There is a clear lack of fundamental insights into disease mechanisms in HCM.
That is, the molecular pathways regulating the key phenotypic components of HCM discussed above are not understood, and this severely limits options for therapeutic intervention. These molecular pathways should be thoroughly explored to identify novel translational opportunities. The following strategies should be considered: is conceivable that an siRNA or similar anti-sense RNA sequence could be generated that distinguishes between a mutant and non-mutant allele at the level of mRNA. Such sequences could target the disease causing mutation itself, or other silent mutations (single nucleotide polymorphisms) that are non-disease causing but still distinguish the mutated allele from the normal. Perhaps the most challenging hurdle would be to generate a proper siRNA that selectively targets the mutant allele, and to rigorously validate it in some sort of cell-based assay (see below for use of induced pluripotent stem (iPS) cells for this and other purposes). Other significant hurdles would include delivery of said siRNA to the hearts of patients (though this has been accomplished to some extent in animal models), and maintenance of siRNA levels chronically so that mutant gene expression is silenced long-term (and this has also been achieved to some degree with antagonists of miRNAs, so-called antagomirs. 70 Other approaches with sequence-specific oligonucleotides, such as catalytic
RNAs that also target mutant mRNA, or even zinc-finger directed nucleases that could selectively target the mutant allele at the level of the DNA, should also be considered.
Indeed, zinc-finger-directed transcription factor nucleases can selectively target DNA sequences in mammals as a means of achieving gene deletion or even correcting a point mutation. 71 The concept would be to target polymorphisms anywhere within the DNA of the gene itself that are specific to the disease allele, as a means of selectively inactivating it, or even selectively changing the mutation back to the non-mutant sequence. Proof-of-concept for such an approach in cells and animal models, and delivery of these alternate platforms would also be considerable hurdles to overcome.
Regardless of these and other technical obstacles, approaches, such as those discussed here, have emerged that might render themselves to treatment of HCM and offer a longterm therapy that would delay disease progression in a meaningful manner.
B. Characterization of the evolution of HCM phenotypes
Recomendation: Develop new research initiatives to define novel approaches to prevent or delay the development of pathological HCM phenotypes. Our view is that HCM mutations cause pathological phenotypes by activating specific signaling pathways.
It is important to utilize existing and new mouse models of HCM to better characterize the evolution of the HCM phenotypes and the pathways regulating them, and to test whether these are also activated in HCM patients. These studies should identify the aberrant activation of those signaling cascades that ultimately induce pathological remodeling and altered mechanical and electrical function. We believe that the focus should be placed on knock-in models rather than transgenics since they appear to more closely recapitulate human disease and maintain protein-protein interactions that knockouts cannot. We propose the following research directions: handling. These studies could employ both targeted signaling pathway (i.e. "best guess") approaches based on prior studies (reviewed in 72, 73 ) and unbiased proteomic analyses.
Translational studies should then be designed to interrupt putative HCM-inducing signaling cascades to determine if disease phenotypes can be prevented or delayed.
HCM phenotype-inducing or perpetuating signaling pathways identified in animal models should ideally be studied in samples from human HCM hearts to validate candidate pathways for novel therapies. An exploration of fundamental signaling pathways and transcript profiles (see below) in biopsy specimens from HCM patients would allow not only a determination as to whether transcriptional and pathway profiling findings in mouse HCM models are recapitulated in patients, but could also allow an identification of novel candidate nodal molecules that are disease-promoting or diseaseassociated factors. Subsequent manipulation of these key nodal molecules in mouse models would then allow a determination of their potential promise as drug targets. These could also be tested in larger animal models of HCM including in the rabbit and pig.
Limiting our ability to achieve the above goals is the necessity of obtaining appropriate human LV tissue samples, including from patients who are in the earliest phases of phenotypic expression of disease. It is hoped that novel and safe approaches for percutaneous acquisition of myocardial tissue can be developed so that such samples can be obtained. 74 Better definition of the substrates for ventricular arrhythmias could improve risk stratification for primary prevention of SCD.
Despite limitations intrinsic to the discrepancies between humans and mice related to heart rate, heart size, and repolarization (mostly K) currents, mouse models are an important tool because they offer the possibility of assembling an integrated understanding of arrhythmia mechanisms-from ion channels, to cellular arrhythmia surrogates (after-depolarizations), intercellular coupling, and isolated heart and in vivo arrhythmias. a. An examination of alterations in ion channels employing a biophysical and pharmacological dissection in iPS-derived cardiomyocytes and in adult cardiomyoctyes isolated from mouse models.
Study mechanisms of arrhythmogenesis in mutation-
b. An examination of disturbances in intracellular Ca 2+ that may be central to arrhythmogenesis in HCM. It is hoped that these studies in iPS cell may allow an identification of intrinsic abnormalities of the myocytes in the absence of the complicated in vivo milieu.
3. Develop HCM model systems with atrial tachyarrhythmias so that fundamental mechanisms underlying these arrhythmias can be identified and novel therapeutic approaches can be tested. Factors driving atrial arrythmogenesis are not well-defined, and studies to date have been largely correlative. Longitudinal studies indicate that disease duration and atrial enlargement increase the risk for AF, an arrhythmia that occurs in at least 20% of HCM patients and contributes to thomboembolic events and sudden death. 31 Diastolic dysfunction and left ventricular outflow tract obstruction contribute to atrial remodeling in HCM, but whether invasive strategies to reduce obstruction can attenuate AF is not known.
Assess arrhythmia burden in patients with HCM.
In addition to trying to understand the pathophysiology of arrhythmia generation with mouse models, it is apparent that the burden of arrhythmia, types of arrhythmias, and factors correlating with arrhythmias in patients with HCM is unclear. We suggest that implantable arrhythmia monitoring in patients be employed to explore the relationships between specific arrhythmias and genotype, phenotype, and biomarker expression.
Arrhythmia ascertainment is a significant challenge for HCM studies. A more recent development in long-term monitoring of patients is the implantable arrhythmia monitor. These small MRI-compatible monitoring devices are implanted in the subcutaneous tissue of the chest and can monitor for arrhythmias for up to 3 years. In the broader population, these devices are primarily used in the evaluation of patients with syncope of unclear etiology, to detect AF, and to monitor AF burden. [83] [84] [85] These devices could also be used in HCM patients to explore relationships between arrhythmias, genotype, phenotype, and biomarkers in patients who do not qualify for ICD placement (i.e. patients at lower risk for sudden death). They could also be used to determine the incidence and epidemiology of ventricular tachyarryhthmias and of AF. It is hoped that the approaches outlined above will allow for the generation of more refined criteria for ICD use, a better understanding of mechanisms driving AF, and a clearer delineation of risk factors/markers for atrial and ventricular arrhythmias in HCM patients. 
D. It is uncertain at this

E. Use of iPS cells to study HCM mechanisms.
Reccomendation: Create patient-specific cardiomyocytes for study in culture.
iPS cells were described above. Despite caveats, we believe that validated iPS cellderived human cardiomyocytes should be created for common HCM mutations and should be made available to researchers in order to determine the validity and potential utility of this approach. In addition to their potential value in studying arrhythmogenesis, the physiology and biology of the HCM myocytes carrying various mutations could be examined in isolation (thereby minimizing confounders such as neurohormonal inputs, signals from the matrix, etc. and without the "history" of the in vivo pathology).
III. Basic Initiatives
Introduction. Study of the fundamental mechanisms that are causal in HCM remains an essential component in the quest to diagnose and cure the disorder. Nearly 50 years after the identification of HCM in young adults as an autosomal dominant disease, 88 and 20 years after its linkage to sarcomeric protein mutations 89 , we still do not understand the most proximal mechanism(s) that initiates the disorder. There are hundreds of sarcomere mutations linked to HCM. 90 Approaches to this vast array of mutations must involve a search for common disturbances in the multiple roles of sarcomere proteins in linking metabolic support mechanisms to the dynamics of force generation, maintenance, and relaxation, as complex responders to Ca 2+ signaling, and as dominant Ca 2+ buffers, as determinants of the diastolic state. Given the central role of altered Ca 2+ signaling in regulating pathologic hypertrophy and ventricular remodeling in other disease models, the mechanisms described above may well drive the phenotypic expression of HCM.
Sarcomere proteins are also directly engaged in signal reception, transmission, and transduction, even in the absence of effects on Ca 2+ . 91, 92 Sarcomere signaling involves mechanical feedback through the costamere, integrins, and the extracellular matrix, as well as to the nuclear envelope. Titin and the Z-disk network are also sites of docking of kinases (e.g. PKC), phosphatases (eg. calcineurin), and transcription factors (e.g. MLP), which shuttle back and forth to their sites of regulation in complex pathways.
There is little doubt that further investigations of these signaling networks will reveal new and significant aspects of their role in excitation, contraction and relaxation, and in adaptive and maladapive responses of heart muscle.
We also do not understand how the sequelae of these initiating mechanisms promote the progression to hypertrophy and sudden death. More studies are required, Post-translational modifications of sarcomere proteins may also alter the initiating mechanism as is the case with PKC-dependent phosphorylation of TnI in an HCM model linked to a mutation in TnI. 100 The potential effects of other PTMs such as oxidation, methylation, nitrosylation, and acetylation have not been generally explored. PTMs associated with increased sympatho-adrenergic activity seem especially important to understand. Sudden death in young athletes needs to be better understood in terms of the increased sympatho-adrenergic activity and increased serum catecholamines. 101 This mechanism itself induces hypertrophy, and the relative role of underlying HCM needs to be better understood. There is a greater prevalence in sudden death in young male athletes, and the incidence in pre-pubertal athletes appears less frequent. Thus, issues related to the effects of androgen-and estrogen-related signaling networks needs further study in mouse models. 102, 103 B. Recommendation: Investigate alterations in metabolism in HCM.
1. Characterize any alterations in metabolism and determine whether correcting these can prevent or rescue the hypertrophic phenotype. Studies in the past decade have consistently demonstrated that myocardial energy metabolism is impaired in HCM. [104] [105] [106] [107] [108] In patients harboring mutations of β-myosin heavy chain, cardiac troponin T, or myosinbinding protein C, direct measurement of cardiac energetics by 31 P NMR spectroscopy showed a ~30% reduction of phosphocreatine to ATP ratio (PCr/ATP) suggesting a significant depletion of energy reserve in the heart. 104, 107 Importantly, this impairment occurred independent of the specific mutation or the presence of cardiac hypertrophy. 104 Similar observations have been made in transgenic hearts expressing a variety of mutant proteins. 106, 108 Furthermore, by performing 31 P NMR spectroscopy of isolated perfused mouse heart, it is possible to measure systolic and diastolic function simultaneously with assessment of cellular energetics and thermodynamic status. In these studies, impaired energetics was found to precede cardiac hypertrophy and systolic dysfunction but coincided with the development of diastolic dysfunction. 108 The depletion of energy reserve compromises the thermodynamic efficiency of ATP hydrolysis (i.e. reduces the free energy release of ATP hydrolysis). 109 Such a reduction impairs the function of some high free-energy requiring ATPases, such as SERCA2a, myosin ATPase and Na + /K + ATPase, all critical to myofibril contraction-relaxation and ion homeostasis. [109] [110] [111] This raises the speculation that defects in energetics may contribute to the diastolic dysfunction and arrhythmias often observed in this disease.
Either increased energy expenditure or reduced energy supply can account for the lower energy reserve in the heart. Altered myofilament function caused by the mutations (e.g. altered calcium sensitivity of the myofilament, impaired actin-myosin interaction, and increased myosin ATPase activity) has been shown in a number of recent studies. [112] [113] [114] These defects increase energy demand or decrease energy efficiency in myofibril contraction, and thus may constitute an important mechanism for impaired myocardial energetics. On the energy supply side, mitochondrial dysfunction and altered substrate metabolism have also been reported in animal models and patients. 107, 115, 116 However, these changes are not observed in every mutant model. 117 It is also important to distinguish the primary versus the secondary changes in cardiac metabolism due to severe cardiac fibrosis and heart failure in this disease. As highlighted in several sections of this document, studies in the early stage of the disease before the development of a full-blown cardiomyopathy are of critical importance.
Although the impairment of energy metabolism has been widely observed in HCM, its role in the pathogenesis and progression of the disease has not been defined.
Very limited information about cardiac energetics in patients with familial HCM is available and none of the data were collected from patients at early stages of the disease.
It is not clear whether the decreased energy reserve in the heart of hypertrophic cardiomyopathy patients is a primary abnormality or secondary to myocardial remodeling. Thus, it will be extremely informative to include a 31 There is now accumulating evidence suggesting that impaired energy metabolism is a common feature in most of the cardiomyopathies caused by mutations of sarcomere proteins. This may represent an excellent target for therapeutic interventions once we determine the energetic element is critical for the progression of the disease. In animal models where changes of myocardial energetics have been observed before the development of hypertrophy and failure, there is a good opportunity to determine whether interventions that either improve energy efficiency or increase energy supply rescue the cardiomyopathy phenotype. One central question will be whether a normalized cellular energetic status improves ion pump function and reduces the risk of arrhythmia.
Moreover, strategies that reduce the adverse consequences of depleted energy reserve by reducing the energy demand and stabilizing E-C coupling, such as calcium channel blockers, warrant further investigation. 
C. Recommendation: Define the role of the vasculature in HCM pathophysiology
Capillary density in the heart is tightly coupled to cardiomyocyte growth during development. [123] [124] [125] [126] This program is likely recapitulated in the adult heart subjected to injury or physiologic stimulation to ensure adequate perfusion as the myocyte compartment expands, and inhibition of this "matching" effect in microvessels during hypertrophy was recently shown to promote decompensation. [127] [128] [129] More specifically, micro-vessel expansion has been reported during pressure overload myocardial hypertrophy in multiple species, including humans. 124, 128, 130, 131 However, long-standing hypertrophy, especially in adult humans, has been associated with a decrease in capillary density, cardiac decompensation, myocyte death and replacement fibrosis. 124, 132 Abnormalities of the vasculature in HCM are associated with evidence of ischemia, and this is presumed to lead to disease progression. Future studies to examine what role vascular abnormalities play in the phenotypic expression of disease are clearly warranted.
Angiogenesis in the adult heart is likely regulated by two distinct mechanisms (with some potential overlap). The first mechanism is the well-known hypoxia/ischemiainduced response through HIF-1-α, [133] [134] [135] and the second mechanism is associated with a general "stress-response" of the heart following acute hemodynamic overload or exercise/pregnancy-induced hypertrophy. 124, 128, 130, 131, 136, 137 Such a response permits the myocardium to coordinate an increase in microvessels with the ensuing hypertrophic response, despite the absence of overt tissue ischemia. Loss of either mechanism would lead to dysynchrony in vessel and capillary content based on the perfusion requirements of the heart, thereby potentially exacerbating HCM. Future studies that investigate the molecular mechanisms underlying angiogenesis in the HCM heart are warranted, especially since ischemia, driven by both pathologic remodeling of the vasculature and impaired angiogenesis, may well be a key to phenotypes. The interstitial fibrosis associated with HCM is most prominent around arteries and in the subendocardium, suggesting that both perivascular and subendocardial fibrosis 
